Key facts
- It has raised $4.1M; the latest was Seed Round ($4.1M) in Dec 2025.
- Notable investors include Asabys Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Oriva Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Oriva Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oriva Therapeutics
Developer of clinical-stage gynecological therapeutics designed to address chronic diseases with high unmet medical need. The company develops non-hormonal, disease-modifying drug candidates based on novel chemistry targeting validated biological pathways, including assets compatible with conception, programs with demonstrated clinical safety data, and a pipeline progressing through early human trials for endometriosis and uterine fibroids, enabling women with chronic gynecological conditions and healthcare systems to access differentiated treatment options that aim to improve long-term disease control and quality of life.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Website
- orivatherapeutics.com/
- Ownership
- Privately Held (backing)
Oriva Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oriva Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oriva Therapeutics in its N-PORT filings yet. We sweep new filings monthly.